A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial.
Weill Cornell Medicine has been awarded a five-year, $4.2 million grant by the National Cancer Institute to investigate the molecular mechanisms by which immune cells interact with Epstein-Barr virus to cause lymphoma, particularly in people living with HIV.
The Cornell Board of Trustees voted May 26 to approve the Paul Rubacha Department of Real Estate, to be managed between the College of Architecture, Art and Planning and the Cornell SC Johnson College of Business.
A technique that enables scientists to record gene mutations and patterns of gene activity in individual cells has been extended to cover RNA splicing as well, in a study co-led by researchers at Weill Cornell Medicine.
A team has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including omicron. Their discovery could lead to more potent vaccines and new antibody-based treatments.
The new additions have expertise in a broad range of computing and information science fields and will shape the next generation of tech leaders and innovators.